Weekly Research Analysts’ Ratings Changes for Celcuity (CELC)

Several brokerages have updated their recommendations and price targets on shares of Celcuity (NASDAQ: CELC) in the last few weeks:

• 3/28/2026 – Celcuity was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/26/2026 – Celcuity had its price target raised by Stifel Nicolaus from $115.00 to $125.00. They now have a “buy” rating on the stock.
• 3/26/2026 – Celcuity had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $122.00 price target on the stock.
• 3/17/2026 – Celcuity had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $122.00 price target on the stock.
• 3/12/2026 – Celcuity had its “outperform” rating reaffirmed by Wolfe Research. They now have a $110.00 price target on the stock.
• 3/10/2026 – Celcuity had its price target raised by Needham & Company LLC from $95.00 to $122.00. They now have a “buy” rating on the stock.

Insider Transactions at Celcuity

In other Celcuity news, Director David Dalvey sold 20,000 shares of the stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the transaction, the director owned 90,000 shares in the company, valued at $10,802,700. This trade represents a 18.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 15.78% of the stock is owned by insiders.

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.